AOD-9604 is one of the few peptides with a specifically Australian research history, developed at Monash University and studied for fat metabolism pathways. Here is what the evidence shows and what legal access looks like.
This article is for general educational purposes only and does not constitute medical advice. AOD-9604 is a prescription-only medicine in Australia requiring assessment by an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
AOD-9604 holds a genuinely unique position in the Australian peptide landscape. It is one of the very few therapeutic peptides with a specifically Australian research and development history, having been developed at Monash University in Victoria as part of research examining the fat metabolism properties of human growth hormone. That local origin makes it worth understanding properly rather than treating it as just another imported compound.
Developed at Monash University, Victoria. One of the few therapeutic peptides with a specifically Australian research and development history.
Studied for fat metabolism and lipolysis pathways, specifically designed to isolate the fat-burning properties of growth hormone from its broader hormonal effects.
Schedule 4 prescription-only medicine in Australia. Requires a valid prescription from an AHPRA-registered doctor and dispensing through a licensed compounding pharmacy.
AOD-9604 stands for Anti-Obesity Drug 9604. It is a synthetic peptide fragment derived from the C-terminus of human growth hormone, specifically the amino acid sequence from position 177 to 191 of the growth hormone molecule. The rationale for isolating this fragment was the observation that the fat metabolism effects of growth hormone appeared to be associated with a specific region of the molecule that could potentially be separated from the growth-promoting and insulin-desensitising effects of full growth hormone.
The development goal was to create a compound that could interact with fat metabolism pathways, specifically lipolysis and the inhibition of lipogenesis, without the broader systemic hormonal effects associated with full growth hormone administration. This is what distinguishes AOD-9604 from other growth hormone-related compounds in the peptide space.
AOD-9604 was developed through research at Monash University led by Professor Alex Coghlan. The research programme investigated the hypothesis that the fat metabolism effects of growth hormone were localised to a specific fragment of the molecule, and that this fragment could be developed as a standalone compound. This work led to a clinical development programme that progressed through several phases of human clinical trials.
At one point during its development, AOD-9604 received approval from the Australian TGA as a food additive ingredient, which was a notable regulatory milestone that reflected the safety data accumulated through its clinical development. The compound was subsequently investigated for weight management applications in clinical trial settings, making it one of the more clinically investigated peptides available through Australian compounding pharmacies.
Research into AOD-9604 has examined its interaction with lipolysis pathways, specifically its potential to stimulate the breakdown of fat stores while inhibiting the formation of new fat from non-fat sources. The proposed mechanism involves interaction with the beta-3 adrenergic receptor, which plays a role in fat metabolism regulation, rather than through the growth hormone receptor pathway used by full growth hormone.
Human clinical trials examined AOD-9604 primarily in the context of weight management, investigating its effects on body composition and fat metabolism markers. The clinical data from these trials is more developed than for most peptides discussed in the Australian market, reflecting the formal pharmaceutical development pathway the compound went through rather than the research-use pathway typical of most compounding pharmacy peptides.
AOD-9604 and IGF-1: One of the key research findings of interest for AOD-9604 is that it does not appear to stimulate IGF-1 production in the way that full growth hormone does. IGF-1 elevation is a significant consideration with growth hormone pathway compounds because of its effects on blood glucose regulation and the monitoring requirements it creates. AOD-9604's research profile in this respect distinguishes it from other growth hormone-related compounds, though a doctor assessment of any individual's circumstances remains the appropriate starting point.
In the Australian weight management peptide landscape, AOD-9604 sits in a different category from GLP-1 receptor agonists like semaglutide and tirzepatide, which work through appetite and gastric emptying mechanisms. AOD-9604's proposed mechanism is more directly focused on fat metabolism at a cellular level, making it a different approach rather than an alternative to the same mechanism.
It also differs from other growth hormone pathway compounds like CJC-1295 and Ipamorelin in that it is not a growth hormone secretagogue. It does not stimulate the pituitary to release more growth hormone. It is a fragment of growth hormone itself, designed to interact with specific fat metabolism pathways without the broader hormonal signalling that full growth hormone or its secretagogues produce.
AOD-9604 is a Schedule 4 prescription-only medicine in Australia and can be legally accessed when prescribed by an AHPRA-registered medical practitioner following a clinical assessment and dispensed through a licensed compounding pharmacy. It is available through UHD BioHealth's standard assessment pathway.
Start with a free assessment. A doctor reviews your health picture and builds a protocol around your specific situation. No cost until you choose to proceed.